Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program
Objective: To confirm: 1) clinical efficacy and safety of once-daily oral ampreloxetine in a 4-week double-blind (DB), placebo-controlled (PC) study (NCT03750552); 2) durability of efficacy…Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease
Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes
Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…Euphoria-inducing lead contacts: mapping of image and electrophysiology in Parkinson’s disease
Objective: We characterized stimulation-induced euphoria during the programming of STN DBS. The lead contacts where euphoria was elicited were characterized anatomically and electrophysiologically. Background: Mood…Predicting the influence of deep brain stimulation on Parkinson’s disease gait freezing
Objective: Before the deep brain stimulation of the subthalamic nucleus (STN-DBS) an individual patient clinical predictor would be useful to inform the patient about freezing…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Gut Microbiote Distinctive Features and Microbiota-Metabolome Profile in Parkinson’s Disease: Focus on Levodopa and LCIG
Objective: The aim of this work was to study the microbiome of PD patients, studying the effect of dopaminergic drugs mainly focusing on the effect…Effectiveness of dopaminergic drugs on motor symptoms in Parkinson’s disease patients with deep brain stimulation of subthalamic nucleus
Objective: To compare the effectiveness of dopaminergic drugs on motor symptoms assessed by UPDRS- III in Parkinson’s disease patients pre and post deep brain stimulation…Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on early morning-OFF (EMO) pattern. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor, was…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 149
- Next Page »